Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Heart

Volumn 93, Issue 9, 2007, Pages 1081-1086

  Briggs, Andrew ^a   Mihaylova, Borislava ^b   Sculpher, Mark ^c   Hall, Alistair ^d   Wolstenholme, Jane ^b   Simoons, Maarten ^e   Deckers, Jaap ^e   Ferrari, Roberto ^f,g   Remme, Willem J ^h   Bertrand, Michel ⁱ   Fox, Kim ^j  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF FERRARA   (Italy)

^g IRCCS   (Italy)

^h Sticares Cardiovascular Research Foundation   (Netherlands)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEATH; DRUG COST; FEMALE; HEART ARREST; HEART INFARCTION; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION;

EID: 34548161388     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.086728     Document Type: Article

References (27)

1. Yusuf S, Pepine CJ, Garces C, et al. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
2. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischaemic events after myocardial infarction: results of the survival and ventricular enlargement trial. Circulation 1994;90:1731-8.
3. The Heart Outcomes Prevention Evaluation Study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
4. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
5. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-71,.
6. Matsumoto K, Morishita R, Moriguchi A, et al. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension 2001;37:270-4.
7. Fox KM, for The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
8. NICE. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence, 2004.
9. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409.
10. British National Formulary. No 49. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2005.
11. Department of Health. Prescription cost analysis: England 2003. London: Department of Health, 2004.
12. NHS Executive. Trust financial returns. Leeds: NHS Executive, 2004.
13. National Assembly for Wales. Welsh Health Survey 1998: results of the second Welsh Health Survey. Cardiff: Government Statistical Service, 1999.
14. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-12.
15. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
16. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28.
17. Deckers JW, Goedhart DM, Boersma E, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006;27:796-801.
18. Briggs AH, Goeree R, Blockhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290- 308.
19. Van Hout BA, AI MJ, Gordon GS, et al. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994;3:309-19.
20. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
21. Campeau L. Grading of angina pectoris. Circulation 1976;54:522-3.
22. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300-3.
23. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.
24. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
25. Lamy A, Yusuf S, Pogue J, et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107:960-5.
26. Braunwald E, Domanski MJ, Fowler SE, for the PEACE Trial investigators, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
27. Mayor S. NHS agrees 7% price reduction for prescription drugs for next five years. BMJ 2004;329:1128.